Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
Imugene Limited (ASX:IMU) is a Sydney-based clinical-stage immuno-oncology company developing immunotherapies that activate the immune system to treat cancer. Its pipeline includes azer-cel, an allogeneic CAR T cell therapy in Phase 1 for relapsed/refractory non-Hodgkin lymphoma and B-cell acute lymphoblastic leukaemia. CF33 VAXINIA, an oncolytic virus, and CF33 CD19 CAR T cell therapy are both in Phase 1 for solid tumours. HER-VAXX, a B-cell cancer vaccine, has completed Phase 2 in metastatic gastric cancer. PD1-Vaxx is in Phase 2 for non-small cell lung cancer, and Neo-POLEM is in Phase 2 for MSI-high colorectal cancer.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Pengana Capital Group have invested in Imugene Ltd (ASX:IMU).
Thesis Tracker does not currently hold fund manager commentary on Imugene in this dataset, so no opportunities or catalysts can be summarised.
Thesis Tracker does not currently hold fund manager commentary on Imugene in this dataset, so no risks can be summarised.
Imugene Limited is a Sydney-based clinical-stage immuno-oncology company developing immunotherapies that activate the immune system to treat cancer. Its pipeline includes azer-cel, an allogeneic CAR T cell therapy in Phase 1 for relapsed/refractory non-Hodgkin lymphoma and B-cell acute lymphoblastic leukaemia. CF33 VAXINIA, an oncolytic virus, and CF33 CD19 CAR T cell therapy are both in Phase 1 for solid tumours. HER-VAXX, a B-cell cancer vaccine, has completed Phase 2 in metastatic gastric cancer. PD1-Vaxx is in Phase 2 for non-small cell lung cancer, and Neo-POLEM is in Phase 2 for MSI-high colorectal cancer.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.